ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TYSABRI
Colorectal disorders
Multiple sclerosis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TYSABRI Rx

Generic Name and Formulations:
Natalizumab 300mg/15mL; soln for IV infusion after dilution; preservative-free.

Company:
Biogen

Therapeutic Use:

Indications for TYSABRI:

In moderately-to-severely active Crohn's disease: to induce and maintain clinical response and remission in adult patients with evidence of inflammation who have had inadequate response to or are intolerant to conventional therapy and TNF-α inhibitors.

Adult:

≥18yrs: Give by IV infusion over 1hr; monitor during and for 1hr post-infusion. 300mg every 4 weeks. Discontinue after 12 weeks of induction therapy if no therapeutic response, or if unable to taper off chronic concomitant steroids within 6 months of starting therapy. May continue with aminosalicylates.

Children:

<18yrs: not established.

Contraindications:

Progressive multifocal leukoencephalopathy (PML).

Warnings/Precautions:

Increased risk of PML with longer treatment duration (>2yrs), prior treatment with immunosuppressants, and/or presence of anti-JCV antibodies. Monitor for signs/symptoms of PML; withhold if develops. Test patients for anti-JCV antibody status prior to or during treatment if status unknown; patients with negative status should be retested periodically. Reevaluate periodically (at 3 months and 6 months post-infusion, every 6 months thereafter, and for at least 6 months after discontinuation). MS: obtain MRI scan prior to initiating therapy. Risk of JCV granule cell neuronopathy; manage similarly to PML if develops. Monitor for signs/symptoms of herpes encephalitis and meningitis; discontinue and treat if occurs. Refer for retinal screening if eye symptoms develop; consider discontinuing therapy if acute retinal necrosis is confirmed. Discontinue if jaundice or liver injury occurs. Immunosuppression. Monitor for infections. Vaccinations. Elderly. Pregnancy. Nursing mothers.

Interactions:

Concomitant other immunosuppressants or TNF-α inhibitors: not recommended.

Pharmacological Class:

Immunomodulator (integrin receptor antagonist).

Adverse Reactions:

Headache, fatigue, arthralgia, infections, depression, pain in extremity, abdominal discomfort, diarrhea NOS, nausea, rash; immune reconstitution syndrome (monitor), hypersensitivity reactions (discontinue if occurs; do not restart), hepatotoxicity, inj site reactions, antibody formation (if persistent, may substantially reduce efficacy), changes in blood cell counts.

Note:

This product is only available through the TOUCH prescribing program. For more information call (800) 456-2255.

REMS:

YES

Generic Availability:

NO

How Supplied:

Single-use vial—1

Indications for TYSABRI:

Monotherapy for the treatment of relapsing forms of multiple sclerosis (MS).

Adult:

≥18yrs: Give by IV infusion over 1hr; monitor during and for 1hr post-infusion. 300mg every 4 weeks.

Children:

<18yrs: not established.

Contraindications:

Progressive multifocal leukoencephalopathy (PML).

Warnings/Precautions:

Increased risk of PML with longer treatment duration (>2yrs), prior treatment with immunosuppressants, and/or presence of anti-JCV antibodies. Monitor for signs/symptoms of PML; withhold if develops. Test patients for anti-JCV antibody status prior to or during treatment if status unknown; patients with negative status should be retested periodically. Reevaluate periodically (at 3 months and 6 months post-infusion, every 6 months thereafter, and for at least 6 months after discontinuation). MS: obtain MRI scan prior to initiating therapy. Risk of JCV granule cell neuronopathy; manage similarly to PML if develops. Monitor for signs/symptoms of herpes encephalitis and meningitis; discontinue and treat if occurs. Refer for retinal screening if eye symptoms develop; consider discontinuing therapy if acute retinal necrosis is confirmed. Discontinue if jaundice or liver injury occurs. Immunosuppression. Monitor for infections. Vaccinations. Elderly. Pregnancy. Nursing mothers.

Interactions:

Concomitant other immunosuppressants: not recommended.

Pharmacological Class:

Immunomodulator (integrin receptor antagonist).

Adverse Reactions:

Headache, fatigue, arthralgia, infections, depression, pain in extremity, abdominal discomfort, diarrhea NOS, nausea, rash; immune reconstitution syndrome (monitor), hypersensitivity reactions (discontinue if occurs; do not restart), hepatotoxicity, inj site reactions, antibody formation (if persistent, may substantially reduce efficacy), changes in blood cell counts.

Note:

This product is only available through the TOUCH prescribing program. For more information call (800) 456-2255.

REMS:

YES

Generic Availability:

NO

How Supplied:

Single-use vial—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs